Differential expressions of cancer-associated genes and their regulatory miRNAs in colorectal carcinoma

Gene

Volumn 567, Issue 1, 2015, Pages 81-86

  Kara, Murat ^a   Yumrutas, Onder ^b   Ozcan, Onder ^a   Celik, Ozgur Ilhan ^a   Bozgeyik, Esra ^c   Bozgeyik, Ibrahim ^b   Tasdemir, Sener ^d  

^a MUGLA SITKI KOCMAN UNIVERSITY   (Turkey)

^b ADIYAMAN UNIVERSITY   (Turkey)

^c GAZIANTEP UNIVERSITY   (Turkey)

^d ATATURK UNIVERSITY   (Turkey)

Author keywords

ADAMTS1; Colorectal cancer; FHIT; MiRNA; RUNXs; SIRT1; WWOX

Indexed keywords

ADAMTS1 PROTEIN; FRAGILE HISTIDINE TRIAD PROTEIN; MICRORNA; MICRORNA 130A 3P; MICRORNA 132 3P; MICRORNA 133B; MICRORNA 143; MICRORNA 143 3P; MICRORNA 155 5P; MICRORNA 17 5P; MICRORNA 193B 3P; MICRORNA 203A; MICRORNA 205 5P; MICRORNA 21 5P; MICRORNA 222 3P; MICRORNA 27A 3P; MICRORNA 29A 3P; MICRORNA 29B 3P; MICRORNA 301A 3P; MICRORNA 34A 5P; MICRORNA 34C 5P; MICRORNA 378A 3P; MICRORNA 96 5P; RAD51 PROTEIN; SIRTUIN 1; SIRTUIN 2; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG; WW DOMAIN CONTAINING OXIDOREDUCTASE;

ADULT; ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR GENE; UPREGULATION; COLORECTAL TUMOR; GENETIC PREDISPOSITION; GENETICS; MICROFLUIDICS;

COLORECTAL NEOPLASMS; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICROFLUIDICS; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84930683227     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.04.065     Document Type: Article

References (50)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2012, 62(1):10-29.
2. Adams B.D., Kasinski A.L., Slack F.J. Aberrant regulation and function of microRNAs in cancer. Curr. Biol. 2014, 24(16):R762-R776.
3. Ahmed F.E. miRNA as markers for the diagnostic screening of colon cancer. Expert. Rev. Anticancer. Ther. 2014, 14(4):463-485.
4. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136(2):215-233.
5. Geyik E., Igci Y.Z., Pala E., Suner A., Borazan E., Bozgeyik I., Bayraktar E., Bayraktar R., Ergun S., Cakmak E.A., Gokalp A., Arslan A. Investigation of the association between ATP2B4 and ATP5B genes with colorectal cancer. Gene 2014, 540(2):178-182. 10.1016/j.gene.2014.02.050.
6. Hong L., et al. Angiogenesis-related microRNAs in colon cancer. Expert. Opin. Biol. Ther. 2013, 13(1):77-84.
7. Rossi S., et al. microRNAs in colon cancer: a roadmap for discovery. FEBS Lett. 2012, 586(19):3000-3007.
8. Zhou J.-J., et al. MicroRNA regulation network in colorectal cancer metastasis. World J. Biol. Chem. 2014, 5(3):301.
9. Faber C., Kirchner T., Hlubek F. The impact of microRNAs on colorectal cancer. Virchows Arch. 2009, 454(4):359-367.
10. Schetter A.J., Harris C.C. Alterations of microRNAs contribute to colon carcinogenesis. Seminars in Oncology 2011, Elsevier.
11. Dong Y., Yu J., Ng S.S.M. MicroRNA dysregulation as a prognostic biomarker in colorectal cancer. Cancer Manag. Res. 2014, 6:405.
12. Fu J., et al. Identifying microRNA-mRNA regulatory network in colorectal cancer by a combination of expression profile and bioinformatics analysis. BMC Syst. Biol. 2012, 6(1):68.
13. Takahashi M., et al. The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One 2012, 7(10):e46684.
14. Arao Tan I., Ricciardelli C., Russell D.L. The metalloproteinase ADAMTS1: a comprehensive review of its role in tumorigenic and metastatic pathways. Int. J. Cancer 2013, 133(10):2263-2276.
15. Toms D., et al. Progesterone receptor expression in granulosa cells is suppressed by microRNA-378-3p. Mol. Cell. Endocrinol. 2015, 399:95-102.
16. Waters C.E., et al. The FHIT gene product: tumor suppressor and genome "caretaker". Cell. Mol. Life Sci. 2014, 71(23):4577-4587.
17. Lin Y.-x, et al. microRNA-143 protects cells from DNA damage-induced killing by downregulating FHIT expression. Cancer Biother. Radiopharm. 2011, 26(3):365-372.
18. Pitroda S.P., et al. DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy. Sci. Transl. Med. 2014, 6(229). (229ra42-229ra42).
19. Hine C.M., et al. Regulation of Rad51 promoter. Cell Cycle 2014, 13(13):2038-2045.
20. Wang Y., et al. MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res. 2012, 72(16):4037-4046.
21. Gasparini P., et al. Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc. Natl. Acad. Sci. 2014, 111(12):4536-4541.
22. O'Connell R.M., et al. MicroRNA-155 is induced during the macrophage inflammatory response. Proc. Natl. Acad. Sci. 2007, 104(5):1604-1609.
23. Choi Y.E., et al. MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability. eLife 2014, 3.
24. Slattery M.L., et al. Associations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1, and eIF4E and risk of colon and rectal cancer: additional support for a TGF-β signaling pathway. Carcinogenesis 2010, bgq245.
25. Ito Y., Bae S.-C., Chuang L.S.H. The RUNX family: developmental regulators in cancer. Nat. Rev. Cancer 2015, 15(2):81-95.
26. Ben-Ami O., et al. A regulatory interplay between miR-27a and Runx1 during megakaryopoiesis. Proc. Natl. Acad. Sci. 2009, 106(1):238-243.
27. Feng J., et al. MicroRNA-27 enhances differentiation of myeloblasts into granulocytes by post-transcriptionally downregulating Runx1. Br. J. Haematol. 2009, 145(3):412-423.
28. Fischer J.A., et al. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia. Mol. Cancer 2015, 14(1):7.
29. Rossetti S., Sacchi N. RUNX1: a microRNA hub in normal and malignant hematopoiesis. Int. J. Mol. Sci. 2013, 14(1):1566-1588.
30. Viticchie G., et al. MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle 2011, 10(7):1121-1131.
31. Li Z., et al. A microRNA signature for a BMP2-induced osteoblast lineage commitment program. Proc. Natl. Acad. Sci. 2008, 105(37):13906-13911.
32. Zhang Y., et al. A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2. Proc. Natl. Acad. Sci. 2011, 108(24):9863-9868.
33. Chen Z., et al. MicroRNA-148a: a potential therapeutic target for cancer. Gene 2014, 533(1):456-457.
34. Yuan H., Su L., Chen W.Y. The emerging and diverse roles of sirtuins in cancer: a clinical perspective. OncoTargets Ther. 2013, 6:1399.
35. Longo V.D., Kennedy B.K. Sirtuins in aging and age-related disease. Cell 2006, 126(2):257-268.
36. Jung W., et al. SIRT1 expression is associated with good prognosis in colorectal cancer. Korean J. Pathol. 2013, 47(4):332-339.
37. Kim J.R., et al. Expression of SIRT1 and DBC1 is associated with poor prognosis of soft tissue sarcomas. PLoS One 2013, 8(9):e74738.
38. Masui T., et al. Expression of METH-1 and METH-2 in pancreatic cancer. Clin. Cancer Res. 2001, 7(11):3437-3443.
39. Yang X., et al. Down-regulation of mir-221 and mir-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of SIRT1. PLoS One 2014, 9(6):e98833.
40. Li L., et al. MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin. Exp. Med. 2013, 13(2):109-117.
41. Li Y., et al. Sirt2 suppresses glioma cell growth through targeting NF-κB"miR-21 axis. Biochem. Biophys. Res. Commun. 2013, 441(3):661-667.
42. Lin J.-T., et al. WWOX suppresses prostate cancer cell progression through cyclin D1-mediated cell cycle arrest in the G1 phase. Cell Cycle 2015, 14(3):408-416.
43. Lai K.W., et al. MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer. Eur. J. Cancer 2010, 46(8):1456-1463.
44. Wang M., et al. Overexpressed miR-301a promotes cell proliferation and invasion by targeting RUNX3 in gastric cancer. J. Gastroenterol. 2013, 48(9):1023-1033.
45. Xu Q., et al. MicroRNA-130a regulates autophagy of endothelial progenitor cells through Runx3. Clin. Exp. Pharmacol. Physiol. 2014, 41(5):351-357.
46. Zuo J., et al. MicroRNA-148a can regulate runt-related transcription factor 3 gene expression via modulation of DNA methyltransferase 1 in gastric cancer. Mol. Cells 2013, 35(4):313-319.
47. Vinall R.L., et al. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int. J. Cancer 2012, 130(11):2526-2538.
48. Zhang L., et al. MiR-132 inhibits expression of SIRT1 and induces pro-inflammatory processes of vascular endothelial inflammation through blockade of the SREBP-1c metabolic pathway. Cardiovasc. Drugs Ther. 2014, 28(4):303-311.
49. Fabbri M., et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. 2007, 104(40):15805-15810.
50. Liu C.J., et al. miR-134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene. Int. J. Cancer 2014, 134(4):811-821.